已收盤 11-20 16:00:00 美东时间
-0.060
-1.71%
今日重点评级关注:Ascendiant Capital:维持Allarity Therapeutics"买入"评级,目标价从11美元升至11.25美元;康托·菲茨杰拉德:维持Cypherpunk Technologies"超配"评级,目标价从4.9美元升至5美元
11-18 15:28
11月18日,Aclaris Therapeutics(ACRS)收跌6.24%,报3.38美元,成交额1069.29万美元,市值5.36亿美元。 行情数据 ...
11-18 07:01
NEW YORK, Nov. 16, 2026 /PRNewswire/ -- Biotech Today News Commentary - Clinical and regulatory news moved several drug developers on a down day for the broader market. The S&P 500 fell 1.92...
11-17 07:34
Aclaris Therapeutics Inc. (NASDAQ:ACRS) CEO Neal Walker affirmed on Monday that the clinical-stage biopharmaceutical company will maintain its core development priorities despite missing primary and secondary endpoints in a Phase 2 atopic dermatitis study. Walker emphasized that Aclaris remains comm...
11-16 22:27
Shares of Take-Two Interactive Software, Inc. (NASDAQ:TTWO) rose sharply in pre-market trading ahead of the November 19 release of its Grand Theft Auto VI game. The company’s CEO said last week that presales were “far in excess” of expectations. Take-Two Interactive shares jumped 4% to $236.68 in pr...
11-16 18:28
Aclaris Therapeutics has initiated a Phase 2b trial of modzatinib for moderate-to-severe lichen planus (LP), targeting oral erosive lichen planus (OLP) as the first cohort. Modzatinib, a dual ITK and JAK3 inhibitor, addresses LP at multiple immune points, potentially offering the first mechanistically complete oral therapy. The trial evaluates efficacy, safety, and tolerability across OLP, cutaneous LP, and lichen planopilaris. No FDA-approved th...
11-16 08:30
Aclaris Therapeutics, Inc. announced that its CEO, Dr. Neal Walker, and senior leadership will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026, at 10:30 AM GMT (5:30 AM ET). A live and archived webcast will be available on the company's website, www.aclaristx.com, for at least 30 days. The company focuses on developing novel treatments for immuno-inflammatory diseases.
11-12 12:30
11月11日,Aclaris Therapeutics(ACRS)收跌2.12%,报4.15美元,成交额581.01万美元,市值6.58亿美元。 行情数据 •...
11-11 06:56
最新财报显示,Aclaris Therapeutics 2026财年第3季度实现: 营业收入:148.1万美元 同比:下降55.11% 净利润:-1851万美元...
11-07 08:00
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.481 million which beat the analyst consensus estimate of ...
11-05 20:22